AUA, ASCO, SUO Release Amendment to Non-Metastatic Muscle Invasive Bladder Cancer Guideline
25 Abril 2024 - 9:21AM
Today, the American Urological Association (AUA), in partnership
with the American Society of Clinical Oncology (ASCO) and the
Society of Urologic Oncology (SUO), released the 2024 clinical
practice guideline amendment for the diagnosis and treatment of
non-metastatic muscle invasive bladder cancer.
There are over 83,000 new cases of bladder cancer and nearly
17,000 bladder cancer deaths estimated for 2024 in the U.S. Up to
50% or more of patients with high-risk non-muscle invasive bladder
cancer (NMIBC) can progress to invasive disease. The male-to-female
ratio is 3:1, and disease incidence increases with age. While rates
of bladder cancer are higher in Caucasians than other ethnicities,
disease-specific survival is worse overall for African
Americans.
“The landscape for the management of muscle-invasive bladder
cancer continues to change with the advent of new therapies,
techniques, and adjuvant care,” said Dr. Jeffrey M. Holzbeierlein,
former SUO president and chair for the guideline amendment. “This
amendment to the previous muscle invasive bladder cancer guidelines
will help clinicians appropriately manage these complex
patients.”
Amendment highlights include:
- Text supporting statements on neoadjuvant/adjuvant
chemotherapy, pelvic lymphadenectomy, and multi-modal bladder
preserving therapy was updated to include newly available data and
updated discussion.
- Recommendations were updated on adjuvant immunotherapy and
considerations for organ sparing procedures.
- The Future Directions section was revised to include additional
text on detection, therapeutics, and surveillance.
This amendment is a comprehensive update to the original 2017
guideline, incorporating revisions made in 2020 and 2024. The
document underwent a rigorous peer review process involving experts
from various professional backgrounds, as conducted by the AUA.
The full updated guideline is now available at
auanet.org/MIBCGuideline
A summary of the Guideline also appears at:
Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of
non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO
guideline (2017; amended 2020, 2024). J Urol. Published online
April 25, 2024. doi:10.1097/JU.0000000000003981
https://www.auajournals.org/doi/10.1097/JU.0000000000003981
Please use this reference to cite the guideline.
About the American Urological Association: Founded in
1902 and headquartered near Baltimore, Maryland, the American
Urological Association is a leading advocate for the specialty of
urology, and has more than 25,000 members throughout the world. The
AUA is a premier urologic association, providing invaluable support
to the urologic community as it pursues its mission of fostering
the highest standards of urologic care through education, research
and the formulation of health policy.
Corey Del Bianco
American Urological Association
443-909-4033
cdelbianco@auanet.org